PTC Therapeutics, Inc. Defined Contribution Plan, Employer Matching Contribution, Percent of Match
PTC Therapeutics, Inc. (PTCT) reported Defined Contribution Plan, Employer Matching Contribution, Percent of Match of 100.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Compensation Related Costs › Defined Contribution Plan
us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch · last filed 2026-02-19
- PTC Therapeutics, Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2025 was 100.00%, a 0.00% change from fiscal 2024.
- PTC Therapeutics, Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2024 was 100.00%, a 0.00% change from fiscal 2023.
- PTC Therapeutics, Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2023 was 100.00%, a 0.00% change from fiscal 2022.
- PTC Therapeutics, Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2022 was 100.00%, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 12 month |
|---|---|
| 2025-12-31 | 100.00% 10-K · filed 2026-02-19 |
| 2024-12-31 | 100.00% 10-K · filed 2026-02-19 |
| 2023-12-31 | 100.00% 10-K · filed 2026-02-19 |
| 2022-12-31 | 100.00% 10-K · filed 2025-02-27 |
| 2021-12-31 | 100.00% 10-K · filed 2024-02-29 |
| 2020-12-31 | 100.00% 10-K · filed 2023-02-21 |
| 2019-12-31 | 100.00% 10-K · filed 2022-02-22 |
| 2018-12-31 | 92.00% 10-K · filed 2021-02-25 |
| 2017-12-31 | 84.00% 10-K · filed 2020-03-02 |
| 2016-12-31 | 50.00% 10-K · filed 2017-03-16 |
| 2015-12-31 | 50.00% 10-K · filed 2016-02-29 |
| 2014-12-31 | 33.00% 10-K · filed 2015-03-02 |
| 2013-12-31 | 20.00% 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |